While ANKRD1 exhibited distinct expression levels between carcinoma and normal tissues, its expression remained stable across different clinical stages of pan-cancer, except for breast invasive carcinoma (BRCA), cervical squamous cell carcinoma (CESC), and KIRP (P < 0.05, Fig. S1). This evidence concerns the gene ANKRD1 and invasive breast carcinoma.